Parameter
| Biomarker | sST2 | Full name | Soluble suppression of tumorigenicity 2 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ~30 kDa | Core Functional Dimensions | Prognostic assessment and fibrosis monitoring | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Myocardium, immune cells, endothelial cells | Test Sample / Technology Platform | Plasma (ELISA, Olink Proximity Extension Assay) | ||
| Pathobiological Mechanisms | Belong to the IL-1 receptor family, as "decoy receptor" IL-33, inhibition of IL-33/ST2L pathway of myocardial protection, promote myocardial fibrosis and ventricular remodeling | ||||
| Clinical Availability Status | Clinical validation/guideline mentions: -ESC guideline (2021) mentions for HF prognostic stratification (class Ⅱb recommendation); -Multiple cohort studies (e.g., PRIDE, TRIUMPH) confirmed its independent prognostic value | ||||
| Notes and Dynamics | Low biological variability (CV<10%), not affected by age, renal function, BMI, suitable for long-term monitoring; Hospitalized in acute HF sST2 > 35 ng/ml mortality or hint 1 HR = 2.46, still rise when the discharge (>35 ng/ml) 54% increased risk of hospitalization; The combination of sST2 > 35ng/ml and Gal-3 can evaluate the "fibrosis burden" of HF patients and predict the efficacy of reversing remodeling | ||||